TEM
NASDAQTempus AI Inc.
Price$81.43+4.91 (+6.42%)
01:15 PM05:15 PM
News · 26 weeks137-46%
2026-04-122026-10-04
Mix6990d
- Insider30(43%)
- SEC Filings18(26%)
- Other13(19%)
- Analyst5(7%)
- Earnings3(4%)
Latest news
25 items- SECAmendment: SEC Form S-4/A filed by Tempus AI Inc.S-4/A - Tempus AI, Inc. (0001717115) (Filer)
- PRTempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026Tempus AI, Inc. (NASDAQ:TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid. At this year’s congress, Tempus will showcase clinical research revealing insights in cancer biology, treatment response and patient outcomes across solid tumors, including prostate, breast, non-small cell lung cancer (NSCLC), renal cell carcinoma and gynecologic malignancies. In addition to scientific presentations, Tempus will highlight its AI-enabled technology and product offerings, including Tempus Lens, Tempus One, and its foundation models, at booths #1068 & #1069. "Across 13 abs
- INSIDERCEO, Diagnostics Schoenherr Thomas Edward sold $873,885 worth of shares (10,281 units at $85.00) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 76,740 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- PRTempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral RegurgitationECG-MR becomes the fourth FDA-cleared Tempus ECG-AI product, spanning arrhythmia, heart function, pulmonary vascular and valvular disease Tempus AI, Inc. (NASDAQ:TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral regurgitation (MR). MR is a common form of heart valve disease where blood leaks backward through the mitral valve. Because early stages are often asymptomatic or manifest as non-specific symptoms like shortness of breath, MR frequently remains undiagnosed until
- INSIDERCEO and Chairman Lefkofsky Eric P sold $19,366,630 worth of shares (250,000 units at $77.47) as part of a pre-agreed trading plan (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- SECSEC Form 144 filed by Tempus AI Inc.144 - Tempus AI, Inc. (0001717115) (Subject)
- PRTempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation ModelTempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion’s RNA Foundation Model. Tempus and Recursion have extended their multi-year data partnership through November 2029. The companies share a mission to use foundation models to advance precision medicine, and entered into a collaboration that was first established in 2023. In connection with the extension of the collaboration’s committed term, the parties agreed to amend the Annual License Fees payable under the original Master Agreement, replacing
- ANALYSTGoldman initiated coverage on Tempus AI with a new price targetGoldman initiated coverage of Tempus AI with a rating of Neutral and set a new price target of $75.00
- INSIDEREVP, Chief Legal Officer Polovin Andrew sold $221,325 worth of shares (2,951 units at $75.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 135,189 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO, Data Fukushima Ryan sold $49,000 worth of shares (700 units at $70.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERChief Accounting Officer Bartolucci Ryan M sold $529,650 worth of shares (7,062 units at $75.00) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 60,804 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO and Chairman Lefkofsky Eric P sold $16,113,802 worth of shares (200,000 units at $80.57) as part of a pre-agreed trading plan (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- SECSEC Form 144 filed by Tempus AI Inc.144 - Tempus AI, Inc. (0001717115) (Subject)
- SECSEC Form 425 filed by Tempus AI Inc.425 - Tempus AI, Inc. (0001717115) (Filed by)
- PRTempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare InnovationThe Initiative Will Make Available 100,000 Disease-Specific Whole Genome Sequences Paired with Longitudinal Clinical Outcomes, with a Long-Term Goal of Reaching 1 Million Genomes Tempus AI, Inc. (NASDAQ:TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. The effort will create the first de-identified multimodal whole-genome sequencing (WGS) dataset built around disease populations and patient outcomes, specifically optimized for AI-driven research. Once this dataset is complete, Tempus plans to expand the effort with the goal of reaching one million genomes. Existing pop
- PRTempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in CardiologyThe Initiative Will Pioneer an AI Agent That Functions as an Extension of the Clinician Team, Capable of Delivering and Coordinating Cardiovascular Care Without Direct Human Intervention Tempus AI, Inc. (NASDAQ:TEM) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to receive an award of up to $9.5 million to build the first autonomous clinical AI agent capable of providing safe and effective care to patients suffering from heart failure. Funding provided through ARPA-H’s ADVOCATE (Agentic AI-EnableD CardioVascular CAre TransfOrmation) program will support the developme
- ANALYSTUBS initiated coverage on Tempus AI with a new price targetUBS initiated coverage of Tempus AI with a rating of Neutral and set a new price target of $70.00
- ANALYSTRothschild & Co Redburn initiated coverage on Tempus AI with a new price targetRothschild & Co Redburn initiated coverage of Tempus AI with a rating of Neutral and set a new price target of $67.00
- PRTempus to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceTempus AI, Inc. (NASDAQ:TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. ET in New York City.A live audio webcast of the conversation will be available here.About TempusTempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in
- INSIDERDirector Doudna Jennifer A sold $44,312 worth of shares (676 units at $65.55) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 25,266 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO, Data Fukushima Ryan sold $1,934,244 worth of shares (30,846 units at $62.71) as part of a pre-agreed trading plan (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERDirector Epstein David R sold $16,388 worth of shares (250 units at $65.55) as part of a pre-agreed trading plan, decreasing direct ownership by 0.80% to 30,844 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- ANALYSTCantor Fitzgerald initiated coverage on Tempus AI with a new price targetCantor Fitzgerald initiated coverage of Tempus AI with a rating of Overweight and set a new price target of $80.00
- INSIDERDirector West Nadja sold $207,000 worth of shares (3,000 units at $69.00) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 31,981 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- ANALYSTTempus AI upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Tempus AI from Neutral to Overweight and set a new price target of $76.00
TEM FAQ
6 questionsWhere does TEM stock trade?
Tempus AI Inc. (TEM) is listed on NASDAQ.What sector and industry is TEM in?
Tempus AI Inc. operates in the Technology sector, Computer Software: Programming Data Processing industry.When did Tempus AI Inc. go public?
Tempus AI Inc. (TEM) completed its IPO in 2024.What are analysts saying about TEM?
Tempus AI Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Neutral on 2026-09-21. Recent price targets cluster around $3500.00.What companies are similar to TEM?
Notable peers in the same industry include GOOGL (Alphabet Inc.), GOOG (Alphabet Inc.), META (Meta Platforms Inc.), APP (Applovin Corporation), NBIS (Nebius Group N.V.). Compare TEM side-by-side with any of them on Quantisnow.How can I track TEM on Quantisnow?
Quantisnow aggregates Tempus AI Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TEM to receive live email and push alerts on every new disclosure.